Traditional antibodydrug conjugate (ADC) development is frequently constrained by low conjugation yield, heterogeneous drugantibody ratio (DAR), linker instability in systemic circulation, and insufficient payload release inside tumour cells. Triglycine (GlyGlyGly, triglycyl motif), acting as a flexible peptide spacer or core cleavable linker segment, has brought substantial performance leaps to ADC bioconjugation, pushing antibody conjugation efficiency up by 300 % compared with conventional short-linker schemes and emerging as a pivotal breakthrough in next-generation ADC research.
The intrinsic structural features of triglycine underpin such prominent improvement. Lacking bulky side-chains, three consecutive glycine residues deliver exceptional conformational flexibility and hydrophilicity. When embedded in linkers, triglycine eliminates steric hindrance between bulky cytotoxic payloads and antibody frameworks, granting bioconjugation reagents unobstructed access to enzymatic-modification sites or engineered reactive residues on the antibody surface. This greatly elevates reaction conversion and shortens incubation time, while drastically reducing incomplete coupling and antibody aggregation that commonly plague traditional linkers. Enzymatic-mediated conjugation systems such as sortase-A-catalysed site‑specific labelling benefit most significantly from triglycine spacers; appropriate triglycine insertion optimises substrate recognition by transpeptidase enzymes and minimises steric interference from payload moieties, thereby realising the three-fold enhancement of overall conjugation efficiency.
Beyond higher coupling yields, triglycine-integrated ADCs achieve more uniform DAR distribution, lowering product heterogeneity. Conjugates with well-defined DAR profiles exhibit consistent pharmacokinetic behaviour, reduced off-target toxicity risk and widened therapeutic windows. In blood circulation, the triglycine-based peptide linker maintains high plasma stability and resists premature non-specific cleavage, preserving ADC integrity during systemic delivery. Once internalised into target tumour cells and trafficked to lysosomes, the triglycine-containing sequence undergoes single-site proteolytic cleavage by lysosomal proteases. This triggers effective liberation of active cytotoxic catabolites. The released payload metabolite carries tailored charge properties: it is uncharged under acidic lysosomal conditions for efficient diffusion into cytosol to exert anti-mitotic cytotoxicity, yet becomes negatively charged at physiological extracellular pH to limit non-specific bystander killing toward adjacent healthy tissues.
Preclinical investigation validates the potency advantage of triglycine-linker ADCs. Against multidrug-resistant tumour cell lines, triglycine-constructed ADCs achieve markedly lower IC₅₀ values relative to classic non-cleavable SMCC-linked counterparts. In xenograft tumour models, triglycine-based ADCs produce robust tumour regression at substantially reduced effective doses, while retaining comparable maximum tolerated dose and serum half-life to benchmark ADC molecules, balancing anti-tumour efficacy and in‑vivo safety profile.
Nevertheless, practical optimisation remains required. Excessively long triglycine stretches may introduce unexpected protease susceptibility in peripheral blood. Researchers need to fine-tune triglycine length and combine it with other functional cleavage motifs to further optimise linker stability-cleavability balance. Collectively, triglycine solves multiple bottlenecks of ADC development including low conjugation efficiency, poor payload release and heterogeneous product quality. It provides a versatile modular building block for site-specific ADC platforms and opens new directions for developing high-performance, clinical-grade antibody-drug conjugates.
